In melanoma patients, the Tcf-1+PD-1+CD8+ T cell population increased in response to anti-CTLA-4 and/or anti-PD-1 treatment and there is the potential that detection of this population can predict patient survival. The gene discussed is CD8A; the disease is melanoma.